MGMT and glioblastoma: The IDH1 mutation, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and 1p 19q deletion have been introduced39 as markers for a low-grade glioma, anaplastic oligoastrocytoma, and glioblastoma, respectively, to predict sensitivity to chemotherapy and develop the appropriate prognosis.